Human Research Protection Program: Policy
Review of Research
Involving Vulnerable Participants
Adopted By: All Campus IRB
Adoption Date: November 10, 2005
Revised: July 10, 2008
Revised: January 22, 2009
Purpose:
This document describes how UW-Madison IRBs review proposed research to determine
whether it provides adequate safeguards for vulnerable research participants.
Definitions
I. Vulnerable participants are those
research participants who are likely to be vulnerable to coercion or undue
influence or lack decision-making capacity, including:
A. those in designated vulnerable groups, such as children, prisoners,
pregnant women, fetuses, neonates, mentally disabled persons, or economically
or educationally disadvantaged persons, and
B. those who may be vulnerable because of physical condition, e.g., severe
illness or pain, psychological or emotional condition, status relationship with
a member of the research team, cultural or political factors or other
circumstances.
Policy
II. To approve research involving
vulnerable participants, UW-Madison IRBs require that the research procedures
include adequate additional safeguards to protect the rights and welfare of
these participants consistent with ethical principles and applicable federal
regulations, state law and institutional policies. Belmont Report; 45 CFR
46.111(b) and 45 CFR 46, Subparts B, C and D; 21 CFR 56.111(b)
and 21 CFR 50, Subpart D; Wisconsin Mental Health Code, WSA 51.61(1)(j),
51.61(4); Wisconsin Protective Services statute, WSA 55.07.
See, also, Applying State Law in Human Subjects Research Policy.
In its Federalwide Assurance (FWA), UW-Madison commits to
applying the federal Common Rule (45 CFR Part 46) to all federally
funded or supported research. UW-Madison applies Subparts B through D of 45
CFR 46 only to research funded by the U.S. Department of Health and Human
Services (“DHHS research”). UW-Madison also applies similar or greater
protections to human research participants in all non-federally funded
research.
III. Department of Veterans Affairs (VA)
policies prohibit the participation of children, prisoners, pregnant women,
neonates and fetuses in VA research protocols.
Procedure
IV. UW-Madison IRBs systematically evaluate
research submitted for initial review, continuing review, or review of changes
of protocol to determine whether the research involves participants likely to
be vulnerable to coercion or undue influence.
V. If the IRB determines that a protocol involves
vulnerable research participants, the IRB considers the following general
criteria:
A. Whether additional safeguards are necessary to protect the welfare,
safety, privacy and confidentiality of these participants.
B. Whether any additional safeguards are described in the protocol.
C. Whether the additional safeguards described in the protocol are
adequate to protect participants.
1. In determining the adequacy of additional protections for vulnerable
participants, the IRBs consider:
a. the degree of risk posed by the research
b. whether the research offers the prospect of
direct benefit to the participant
D. For those vulnerable groups for which specific, additional protections
are designated by ethical principles, federal regulations, state law and
institutional policies, the IRB evaluates whether the protocol complies with
those requirements.
E. The IRB is particularly cognizant of the special problems of research
involving designated vulnerable populations, such as children, prisoners,
pregnant women, mentally disabled persons, or economically or educationally
disadvantaged persons when assessing whether the selection of research
participants is equitable.
F. If an IRB regularly reviews research that involves a vulnerable population,
such as children, prisoners, pregnant women, or handicapped or mentally disabled
persons, consideration shall be given to the inclusion on the IRB of one or
more individuals who are knowledgeable about and experienced in working with
these subjects.
1. For DHHS research involving prisoners:
a. a majority of IRB members (exclusive of
prisoner members) shall have no association with the prison(s) involved, apart
from their membership on the Board, and
b. at least one member shall be a prisoner, or a
prisoner representative with appropriate background and experience to serve in
that capacity, except that where a particular research project is reviewed by
more than one IRB only one IRB need satisfy this requirement.
G. When approving research that involves vulnerable groups, the IRB will
document in its meeting minutes the IRB’s justifications and findings regarding
the determinations stated in the applicable federal regulations or the IRB’s
agreement with the findings and justifications as presented by the
investigator.
VI. IRB Review of Research Involving
Children.
A. UW-Madison IRBs will approve research involving children only if the IRB
finds that the research includes any required additional safeguards outlined in
ethical principles and applicable federal regulations, state laws and
institutional policies. See, Belmont Report; 45 CFR 46,
Subpart D; 21 CFR 50, Subpart D; UW-Madison Federalwide Assurance; Applying
State Law in Human Subjects Research Policy.
B. The IRB may also apply OHRP Guidance - Research with
Children FAQs, authorizing minors to consent to research
participation without parental permission or waiver of permission, if the
research involves solely treatments or procedures for which minors can give
consent outside the research context under state or local laws. For more information,
contact the UW-Madison Office of Administrative Legal Services.
C. For an IRB to approve DHHS research involving children or FDA research
involving children, the IRB must find and document that the research meets the
requirements of one of the following categories of research:
1. The research involves no greater than minimal risk and that adequate
provisions are made for soliciting the assent of the children and the
permission of their parents or guardians, as set forth in 45 CFR 46.408 or 21 CFR
50.55. [45 CFR 46.404; 21 CFR 50.51]
2. That more than minimal risk to children is presented by an intervention
or procedure that holds out the prospect of direct benefit for the individual
subject or by a monitoring procedure that is likely to contribute to the
subject's well-being and all of the following:
a. The risk is justified by the anticipated
benefit to the subjects
b. The relation of the anticipated benefit to
the risk is at least as favorable to the subjects as that presented by available
alternative approaches, and
c. Adequate provisions are made for soliciting
the assent of the children and permission of their parents or guardians, as set
forth in 45 CFR 46.408 or 21 CFR 50.55. [45 CFR 46.405; 21 CFR 50.52]
3. That more than minimal risk to children is presented by an intervention
or procedure that does not hold out the prospect of direct benefit for the
individual subject or by a monitoring procedure which is not likely to
contribute to the well-being of the subject and all of the following:
a. The risk represents a minor increase over
minimal risk
b. The intervention or procedure presents
experiences to subjects that are reasonably commensurate with those inherent in
their actual or expected medical, dental, psychological, social, or educational
situations
c. The intervention or procedure is likely to
yield generalizable knowledge about the subjects' disorder or condition which
is of vital importance for the understanding or amelioration of the subjects'
disorder or condition, and
d. Adequate provisions are made for soliciting
assent of the children and permission of their parents or guardians, as set
forth in 45 CFR 46.408 or 21 CFR 50.55. [45 CFR 46.406; 21 CFR 50.53]
4. For DHHS research, that the research does not meet the requirements of
45 CFR 46.404, 46.405, or 46.406 and all of the
following:
a. The IRB finds that the research presents a
reasonable opportunity to further the understanding, prevention, or alleviation
of a serious problem affecting the health or welfare of children, and
b. The Secretary, after consultation with a
panel of experts in pertinent disciplines (for example: science, medicine,
education, ethics, law) and following opportunity for public review and
comment, has determined either:
i.
That the research in fact satisfies the conditions of 45 CFR 46.404, 46.405, or 46.406, as applicable,
or
ii.
All of the following:
The research presents a reasonable opportunity to further the
understanding, prevention, or alleviation of a serious problem affecting the
health or welfare of children
The research will be conducted in accordance with sound ethical
principles
Adequate provisions are made for soliciting the assent of
children and the permission of their parents or guardians, as set forth in 45
CFR 46.408. [45 CFR 46.407]
5. For FDA regulated research, that the research does not meet the
requirements of 21 CFR 50.51, 21 CFR 50.52, or 21 CFR 50.53 and that:
a. The IRB finds that the research presents a
reasonable opportunity to further the understanding, prevention, or alleviation
of a serious problem affecting the health or welfare of children, and
b. The Commissioner of Food and Drugs, after
consultation with a panel of experts in pertinent disciplines (for example:
science, medicine, education, ethics, law) and following opportunity for public
review and comment, has determined that either of the following is true:
i.
The research in fact satisfies the conditions of 21 CFR 50.51, 21 CFR
50.52, 21 CFR 50.53 above, or
ii.
All of the following are true:
The research presents a reasonable opportunity to further the
understanding, prevention, or alleviation of a serious problem affecting the
health or welfare of children
The research will be conducted in accordance with sound ethical
principles
Adequate provisions are made for soliciting the assent of
children and the permission of their parents or guardians
6. For each protocol approved under 45 CFR 46.406, 45 CFR 46.407, 21 CFR
50.53 or 21 CFR 50.54, the IRB must also find one of the following:
a. The research does NOT involve wards of the state
or any other agency, institution, or entity, or
b. The research meets the criteria for
involvement of wards of the State or any other agency, institution, or entity
(see, Section III.C.7, below).
D. Definitions [45 CFR 46.102, 46.402 and 21 CFR 50.3]
1. The terms research and clinical investigation are deemed
to be synonymous for purposes of this policy.
2. Children are persons who have not attained the legal age for
consent to treatments or procedures involved in the research, under the
applicable law of the jurisdiction in which the research will be conducted.
a. In Wisconsin, “children” are generally those
persons under the age of 18 years. For more information, see, Applying
State Law in Human Subjects Research Policy.
b. In Wisconsin, emancipated minors are not
subject to Subpart D of 45 CFR 46 and are consented as adults. Emancipated
minors include individuals under 18 years of age who are or have been married,
who have given birth or who have been freed from the care, custody and control
of their parents with little likelihood of returning to the care, custody and
control prior to marriage or prior to reaching the age of majority. [WSA
48.375(2)(e), 765.02(2), 880.04(1), 895.037(1)(c)]
c. In Wisconsin, non-emancipated minors may
consent to certain treatment or procedures without parental permission. For
more information, see OHRP Guidance - Research with
Children FAQs and Applying State Law in Human Subjects
Research Policy. Also, consult with the UW-Madison Office of
Administrative Legal Services.
3. Ward means a child who is placed in the legal custody of the
State or other agency, institution, or entity, consistent with applicable
Federal, State, or local law.
4. Parent means a child's biological or adoptive parent.
a. In Wisconsin, a “parent” means either a
biological parent, a husband who has consented to the artificial insemination
of his wife, or a parent by adoption. If the child is a non-marital child
who is not adopted or whose parents do not subsequently intermarry,
"parent" includes a person who has acknowledged paternity by law or
been adjudicated to be the biological father. "Parent" does not
include any person whose parental rights have been terminated. WSA 48.02(13)
5. Guardian means an individual who is authorized under applicable state
or local law to consent on behalf of a child to general medical care when
general medical care includes participation in research. In FDA regulated
research, a guardian also means an individual who is authorized under
applicable state or local law to consent on behalf of a child to participate in
research.
a. Under Wisconsin law, in addition to a
“parent,” as defined, above, a court-appointed “guardian” for an unemancipated
child under the age of 18 has the authority to consent to major medical,
psychiatric and surgical treatment. [WSA 48.023(1)] A relative of a minor may
be appointed as a minor’s “guardian.” [WSA 48.02, 48.023]. For more
information, see, Applying State Law in Human Subjects Research
Policy.
6. Assent means a child's affirmative agreement to participate in
research. Mere failure to object should not, absent affirmative agreement, be
construed as assent.
7. Permission means the agreement of parent(s) or guardian to the
participation of their child or ward in research. In FDA regulated research,
permission must be obtained in compliance with Subpart B of 21 CFR 50 and must
include the elements of informed consent described in 21 CFR 50.25.
8. Minimal risk means that the probability and magnitude of harm or
discomfort anticipated in the research are not greater in and of themselves
than those ordinarily encountered in daily life or during the performance of
routine physical or psychological examinations or tests.
E. Assent by Children to
Research Participation
1. When reviewing research involving children, UW-Madison IRBs will ensure
that adequate provisions are made for soliciting the assent of the children
when, in the judgment of the IRB, the children are capable of providing assent.
[45 CFR 46.408(a); 21 CFR 50.55]
2. In determining whether children are capable of assenting, the IRB shall
take into account the ages, maturity, and psychological state of the children
involved. This judgment may be made for all children to be involved in research
under a particular protocol, or for each child, as the IRB deems appropriate..
3. Assent by children is not a necessary condition for proceeding with the
research if the IRB determines that:
a. the capability of some or all of the children
is so limited that they cannot reasonably be consulted, or
b. the intervention or procedure involved in the
research holds out a prospect of direct benefit that is important to the health
or well-being of the children and is available only in the context of the
research,.
4. Even where the IRB determines that the children are capable of
assenting, the IRB may still waive the assent requirement if it finds and
documents all of the following:
a. The research involves no more than minimal
risk to the subjects
b. The waiver will not adversely affect the
rights and welfare of the children
c. The clinical investigation could not
practicably be carried out without the waiver, and
d. Whenever appropriate, the children will be
provided with additional pertinent information after participation. [See, 45
CFR 46.116; 21 CFR 50.55(d)]
5. When the IRB determines that assent is required, it will also determine
whether and how assent must be documented. [45 CFR 46.408(a); 21 CFR 50.55]
a. Investigators who plan to enroll children in
their protocols should describe in their protocol applications the assent
process that will be followed, taking into account the age ranges of the
children, as well as the maturity and physical and psychological state of the
children.
b. Even if a child is too young to provide
assent, investigators should consider and describe in their applications to the
IRB how the investigator will identify and respond to situations where the
child does not want to participate.
c. Research involving preschool age children
must indicate when the research will be conducted (e.g., during the month of
October) and the duration of the activities.
d. Respect for a child’s unwillingness to
participate is especially critical in research that does not have a therapeutic
intent and that exposes the child to some risk.
See, Assent by Children
Guidance
HS IRBs Policy for Obtaining Assent of Minors
F. Permission by or Consent of Parent or Guardian
1. When reviewing research involving children, UW-Madison IRBs will assure
that adequate provisions are made for soliciting the permission or consent of
each child's parents or guardian when required by ethical principles and
applicable federal regulations, state laws and institutional policies. (See, Section
III.B and III.D.2, above, for a description of when children under the age
of 18 may consent to research participation without the permission of parents
or guardians.) [45 CFR 46.408(b-d); 21 CFR 50.55]
2. Where parental permission is to be obtained, the IRB may find that the
permission of one parent is sufficient for research to be conducted under 45
CFR 46.404 or 46.405 or 21 CFR 50.51
or 50.52.
3. Where research is covered by 45 CFR 46.406 or 46.407 or 21 CFR 50.53
or 50.54 and permission is to be obtained from parents, both parents must give
their permission unless one parent is deceased, unknown, incompetent, or not
reasonably available, or when only one parent has legal responsibility for the
care and custody of the child.
4. For research not regulated by the FDA, if the IRB determines that a
research protocol is designed for conditions or for a subject population for which
parental or guardian permission is not a reasonable requirement to protect the
subjects (for example, neglected or abused children), the IRB may waive informed
consent under 45 CFR 46, Subpart A, and the parental or guardian permission
requirements of 45 CFR 46.408(b) when authorized by ethical principles and applicable
federal regulations, state law and institutional policies. [45 CFR 46.116,
46.408(c)]
To waive requirement of consent or permission of a
parent or guardian in these circumstances, the IRB must find that:
a. That an appropriate mechanism for protecting
the children who will participate as subjects in the research is substituted
taking into account the nature and purpose of the activities described in the
protocol, the risk and anticipated benefit to the research subjects, and their
age, maturity, status, and condition, and
b. That the waiver is not inconsistent with
federal, state, or local law.
5. Consent cannot be waived in FDA-regulated studies except in limited
circumstances. See, Informed Consent Policy, Sec. IV.D.2
6. Permission by parents or guardians shall be documented in accordance
with and to the extent required by 45 CFR 46.117 or 21 CFR
50.27.
a. The consent form must indicate that either
the child may withdraw or the parent may withdraw the child from the research
at any time.
7. Before a person other than the parent or court-appointed guardian of a
child can give permission for a child to take part in research, the
investigator must consult with UW-Madison legal services office to confirm that
the person is authorized under applicable law to consent on behalf of a child
to general medical care.
G. Children who are Wards of State
1. When reviewing research involving children who are wards of the state
or any other agency, institution, or entity, UW-Madison IRBs will assure that the
research includes the special protections in 45 CFR 46, Subpart D and/or 21 CFR
50.56, when applicable.
a. Children who are wards of the State or any
other agency, institution, or entity can be included in research approved under
45 CFR 46.406 or 46.407 or 21 CFR 50.53 or 50.54 only if such research is:
i. Related to their status as wards, or
ii. Conducted in schools, camps, hospitals,
institutions, or similar settings in which the majority of children involved as
subjects are not wards.
b. If the research is approved under paragraph
(a) of this section, the IRB shall require appointment of an advocate for each
child who is a ward, in addition to any other individual acting on behalf of
the child as guardian or in loco parentis. One individual may serve as advocate
for more than one child. The advocate shall be an individual who has the background
and experience to act in, and agrees to act in, the best interests of the child
for the duration of the child's participation in the research and who is not
associated in any way (except in the role as advocate or member of the IRB)
with the research, the investigator(s), or the guardian organization. [45 CFR
46.409; 21 CFR 50.56]
H. The exemption at 45 CFR 46.101(b)(2), for research involving survey or
interview procedures or observation of public behavior, does not apply to
research with children, governed by 45 CFR 46, Subpart D, except for
research involving observations of public behavior when the investigator(s) do
not participate in the activities being observed.
I. In addition to any ethical principles and applicable federal
regulations and state laws governing research with children, UW-Madison IRBs
apply the following specific additional protections:
1. SBS IRB and ED IRB:
a. Written assent to participate in research is
required of a child who is 11 years old or older
b. For runaways and homeless children, waiver of
parental consent for participation in research is permitted if parents cannot
be located, research is not more than minimal risk and research cannot be
carried out without the waiver.
2. HS IRB and MR IRB:
a. Minors should be included to the fullest
degree possible in decisions about their own health care, including
experimental health care.
b. The HS IRB and MR IRB apply different
protections depending on whether the research is therapeutic or non-therapeutic
and the age of the child. For more information, see, HS IRBs Policy for
Obtaining Assent of Minors.
i.
Assent of minors is required in protocols dealing with non-therapeutic
research unless the minor otherwise lacks the capacity to consent.
ii.
Assent in non-therapeutic protocols shall be obtained from children with
normal developmental status aged 7 and older.
iii.
Phase I trials should generally be considered therapeutic studies if
they hold out the prospect of direct benefit.
iv.
For therapeutic research, minors should be included to the degree
possible in decisions about their health care, but parental consent is required
to be documented.
v.
The HS IRB includes more than one member who is a child advocate. These
child advocates are asked to be primary reviewers on research involving
children and their expertise is requested on issues relating to involving
children in research.
VII. IRB Review of Research Involving
Prisoners
A. Recognizing that prisoners may be under constraints because of their
incarceration which could affect their ability to make a truly voluntary and
uncoerced decision whether or not to participate as subjects in research, UW-Madison
IRBs will approve research involving prisoners only if the IRB finds that the
research includes any required additional safeguards outlined in ethical
principles and applicable federal regulations, state laws and institutional
policies. Belmont Report; 45 CFR 46, Subpart C; 21 CFR 56.111(b); UW-Madison
Federalwide Assurance; Applying State Law in Human Subjects Research
Policy.
B. Definitions
1. Prisoner means any individual involuntarily confined or detained
in a penal institution, including individuals sentenced to such an institution
under a criminal or civil statute, individuals detained in other facilities by
virtue of statutes or commitment procedures which provide alternatives to
criminal prosecution or incarceration in a penal institution, and individuals
detained pending arraignment, trial, or sentencing. This includes situations
where a participant becomes a prisoner after the research has commenced.
2. Minimal risk is the probability and magnitude of physical or
psychological harm that is normally encountered in the daily lives, or in the
routine medical, dental, or psychological examination of healthy persons.
C. DHHS biomedical or behavioral research may include prisoners as
subjects only if the IRB finds and documents
the following requirements of 45 CFR 46.306. Except
as provided below, biomedical or behavioral research conducted or supported by
DHHS shall not involve prisoners as subjects:
1. The institution responsible for the conduct of the
research has certified to the Secretary of DHHS that the IRB has approved the
research under 45 CFR 46.305, and
2. In the judgment of the Secretary of DHHS, the proposed research
involves solely one of the following:
a. Study of the possible causes, effects, and
processes of incarceration, and of criminal behavior, provided that the study
presents no more than minimal risk and no more than inconvenience to the
subjects
b. Study of prisons as institutional structures
or of prisoners as incarcerated persons, provided that the study presents no
more than minimal risk and no more than inconvenience to the subjects
c. Research on conditions particularly affecting
prisoners as a class (for example, vaccine trials and other research on
hepatitis which is much more prevalent in prisons than elsewhere; and research
on social and psychological problems such as alcoholism, drug addiction, and
sexual assaults) provided that the study may proceed only after the Secretary
has consulted with appropriate experts including experts in penology, medicine,
and ethics, and published notice, in the FEDERAL REGISTER, of his intent to
approve such research, or
d. Research on practices, both innovative and
accepted, which have the intent and reasonable probability of improving the
health or well-being of the subject. In cases in which those studies require
the assignment of prisoners in a manner consistent with protocols approved by
the IRB to control groups which may not benefit from the research, the study
may proceed only after the Secretary has consulted with appropriate experts,
including experts in penology, medicine, and ethics, and published notice, in
the FEDERAL REGISTER, of the intent to approve such research.
e. The HHS Secretarial waiver for certain
epidemiological research conducted or supported by HHS functions as a
fifth category of permissible research.
The criteria for this category are that the research must have as its sole
purpose (i) to describe the prevalence or incidence of a disease by identifying
all cases, or (ii) to study potential risk factor associations for a disease.
The institution still must review the research under subpart C and certify to
OHRP that an appropriately constituted IRB has reviewed the proposal and made
all other required findings under HHS regulations at 45 CFR 46.305(a) and
receive OHRP authorization prior to initiating any research involving
prisoners. All of the other requirements of subpart C apply to research in this
category.
D. To approve federally funded research involving prisoners, UW-Madison
IRBs must find all of the following:
1. The research under review represents one of the categories of research
permissible under Section C.2, above [45 CFR 46.306(a)(2)].
2. Any possible advantages accruing to the prisoner through his or her
participation in the research, when compared to the general living conditions,
medical care, quality of food, amenities and opportunity for earnings in the
prison, are not of such a magnitude that his or her ability to weigh the risks
of the research against the value of such advantages in the limited choice
environment of the prison is impaired.
3. The risks involved in the research are commensurate with risks that
would be accepted by non-prisoner volunteers.
4. Procedures for the selection of subjects within the prison are fair to
all prisoners and immune from arbitrary intervention by prison authorities or
prisoners. Unless the principal investigator provides to the IRB justification
in writing for following some other procedures, control subjects must be
selected randomly from the group of available prisoners who meet the
characteristics needed for that particular research project.
5. The information is presented in language which is understandable to the
subject population
6. Adequate assurance exists that parole boards will not take into account
a prisoner's participation in the research in making decisions regarding
parole, and each prisoner is clearly informed in advance that participation in
the research will have no effect on his or her parole.
7. Where the IRB finds there may be a need for follow-up examination or
care of participants after the end of their participation, adequate provision
has been made for such examination or care, taking into account the varying lengths
of individual prisoners' sentences, and for informing participants of this
fact. [45 CFR 46.305(a)]
E. Federally funded prisoner protocols are reviewed either by the HS IRB
or the SBS IRB.
F. Research targeting prisoners is generally subject to review by the full
IRB with a designated prisoner representative present and a majority of IRB
members having no association with the prison involved. Prisoner protocols are
generally not eligible for expedited initial
review. For those prisoner protocols that are eligible for expedited
continuing review or change of
protocol review, the expedited reviewers will include a prisoner
representative. See, Expedited
Review Policy.
In non-federally funded HS IRB and MR IRB protocols,
if a prisoner is involved only incidentally in research (e.g., treatment trials
for AIDs or cancer or medical records studies), a prisoner representative does
not have to be present at the IRB meeting when the protocol is considered and
approved.
G. When a previously enrolled research participant becomes a prisoner and
the relevant research protocol was not reviewed and approved by the IRB in
accordance with the requirements of 45 CFR 46, Subpart C, the following
procedures apply:
For all federally-funded prisoner protocols:
1. The principal investigator should promptly notify the IRB of this
event.
2. Upon receipt of notification that a previously enrolled research
participant has become a prisoner, if the principal investigator wishes to have
the prisoner participant continue to participate in the research, the IRB
should promptly re-review the protocol in accordance with the requirements of
45 CFR 46, Subpart C.
a. All research interactions and interventions
with, and obtaining identifiable private information about, the now-incarcerated
participant must cease until the requirements of 45 CFR 46, Subpart C have been
satisfied with respect to the relevant protocol.
b. In special circumstances in which the
principal investigator asserts that it is in the best interests of the participant
to remain in the research study while incarcerated, the IRB Chair may determine
that the participant may continue to participate in the research until the
requirements of 45 CFR 46, Subpart C are satisfied.
For non-federally funded HS IRB and MR IRB protocols:
1. The principal investigator should promptly notify the IRB of this
event.
2. Upon receipt of notification that a previously enrolled research
participant has become a prisoner, if the principal investigator wishes to have
the participant continue to participate in the research, the IRB re-reviews the
protocol at the next possible IRB meeting to assure compliance with either 45
CFR 46, Subpart C or another procedure that the IRB determines is similarly or
more protective of the incarcerated participant.
VIII. IRB Review of Research Involving
Pregnant Women, Neonates and Fetuses
A. UW-Madison IRBs will approve research involving pregnant women, fetuses
and neonates only if the IRB finds that the research includes any required
additional safeguards outlined in ethical principles and applicable federal
regulations, state laws and institutional policies. See, Belmont
Report; 45 CFR 46, Subparts B and C; 21 CFR 50, Subparts A and D; 21 CFR 56.107
and 56.111; UW-Madison Federalwide Assurance; Applying State Law in
Human Subjects Research Policy.
B. UW-Madison IRBs will apply the special protections in 45 CFR, Subpart B
to all DHHS research involving pregnant women, human fetuses, neonates of
uncertain viability, or nonviable neonates.
C. The exemptions at 45 CFR 46.101(b)(1) through (6) are applicable to research
involving pregnant women, neonates and fetuses under Subpart B.
D. Definitions [45 CFR 46.202]
1. Dead fetus means a fetus that exhibits neither heartbeat,
spontaneous respiratory activity, spontaneous movement of voluntary muscles,
nor pulsation of the umbilical cord.
2. Delivery means complete separation of the fetus from the woman
by expulsion or extraction or any other means.
3. Fetus means the product of conception from implantation until
delivery.
4. Neonate means a newborn.
5. Nonviable neonate means a neonate after delivery that, although
living, is not viable.
6. Pregnancy encompasses the period of time from implantation until
delivery. A woman shall be assumed to be pregnant if she exhibits any of the
pertinent presumptive signs of pregnancy, such as missed menses, until the
results of a pregnancy test are negative or until delivery.
7. Viable, as it pertains to the neonate, means being able, after
delivery, to survive (given the benefit of available medical therapy) to the
point of independently maintaining heartbeat and respiration. The Secretary may
from time to time, taking into account medical advances, publish in the FEDERAL
REGISTER guidelines to assist in determining whether a neonate is viable for
purposes of this subpart. If a neonate is viable then it may be included in
research only to the extent permitted and in accordance with the requirements
of 45 CFR 46, Subparts A and D.
E. Pregnant women or fetuses may be involved in research if the IRB finds
that all of the following conditions are met [45 CFR 46.204]:
1. Scientifically appropriate, preclinical studies, including studies on
pregnant animals, and clinical studies, including studies on non-pregnant
women, have been conducted and provide data for assessing potential risks to
pregnant women and fetuses
2. Either that the risk to the fetus is caused solely by interventions or
procedures that hold out the prospect of direct benefit for the woman or the
fetus, or
a. if there is no such prospect of benefit:
i.
the risk to the fetus is not greater than minimal, and
ii.
the purpose of the research is the development of important biomedical
knowledge which cannot be obtained by any other means.
3. Any risk is the least possible for achieving the objectives of the
research.
4. No inducements, monetary or otherwise, will be offered to terminate a
pregnancy.
5. Individuals engaged in the research will have no part in any decisions
as to the timing, method, or procedures used to terminate a pregnancy.
6. Individuals engaged in the research will have no part in determining
the viability of a neonate.
7. Consent requirements
a. The pregnant woman’s consent will be obtained
in accord with 45 CFR, Subpart A when:
i.
the research holds out:
the prospect of direct benefit to the pregnant woman
the prospect of a direct benefit both to the pregnant woman and the
fetus, or
no prospect of benefit for the woman nor the fetus
ii.
risk to the fetus is not greater than minimal, and
iii.
the purpose of the research is the development of important biomedical
knowledge that cannot be obtained by any other means.
b. The consent of the pregnant woman and the
father will be obtained in accord with 45 CFR 46, Subpart A when the research
holds out the prospect of direct benefit solely to the fetus.
i.
the father's consent need not be obtained if he is unable to consent
because of unavailability, incompetence, or temporary incapacity or the
pregnancy resulted from rape or incest
c. Each individual providing consent under 45 CFR
46.204(d) or (e) is fully informed regarding the reasonably foreseeable impact
of the research on the fetus or neonate.
d. For children, as defined in 45 CFR 46.402(a),
who are pregnant, assent and permission are obtained in accord with 45 CFR 46,
Subpart D.
F. Neonates of uncertain viability and nonviable
neonates may be involved in research if the IRB finds that all of the
following conditions are met [45 CFR 46.205]:
1. Scientifically appropriate, preclinical and clinical studies have been
conducted and provide data for assessing potential risks to neonates.
2. Each individual providing consent under Sections G.2 or H.5, below,
is fully informed regarding the reasonably foreseeable impact of the research
on the neonate.
3. Individuals engaged in the research will have no part in determining
the viability of a neonate.
4. The requirements of Sections G or H, below, have been met if
applicable.
G. Neonates of uncertain viability. Until it has been ascertained
whether or not a neonate is viable, a neonate may not be involved in research
covered by Subpart B unless the following additional conditions have been met:
1. The IRB determines that:
a. The research holds out the prospect of
enhancing the probability of survival of the neonate to the point of viability,
and any risk is the least possible for achieving that objective, or
b. The purpose of the research is the
development of important biomedical knowledge which cannot be obtained by other
means and there will be no added risk to the neonate resulting from the
research; and
2. The legally effective informed consent of either parent of the neonate
or, if neither parent is able to consent because of unavailability,
incompetence, or temporary incapacity, the legally effective informed consent
of either parent's legally authorized representative is obtained in accord with
45 CFR 46, Subpart A, except that the consent of the father or his legally
authorized representative need not be obtained if the pregnancy resulted from rape
or incest.
H. Nonviable neonates. After delivery nonviable neonates may not be
involved in research covered by Subpart B unless all of the following
additional conditions are met:
1. Vital functions of the neonate will not be artificially maintained.
2. The research will not terminate the heartbeat or respiration of the
neonate.
3. There will be no added risk to the neonate resulting from the research.
4. The purpose of the research is the development of important biomedical
knowledge that cannot be obtained by other means.
5. The legally effective informed consent of both parents of the neonate
is obtained in accord with subpart A of this part, except that the waiver and
alteration provisions of 45 CFR 46.116(c) and (d) do not apply. However, if either
parent is unable to consent because of unavailability, incompetence, or
temporary incapacity, the informed consent of one parent of a nonviable neonate
will suffice to meet the requirements of this paragraph, except that the
consent of the father need not be obtained if the pregnancy resulted from rape
or incest. The consent of a legally authorized representative of either or both
of the parents of a nonviable neonate will not suffice to meet the requirements
of this paragraph.
I. Viable neonates. A neonate, after delivery, that has been determined
to be viable may be included in research only to the extent permitted by and in
accord with the requirements of 45 CFR 46, Subparts A and D. Thus, the
exemptions at 46.101(b)(2), for research involving survey or interview
procedures or observations of public behavior, would not apply. See, 45 CFR
46.204(d).
J. DHHS research that the IRB finds
does not meet the requirements of 45 CFR 46.404, 46.405, or 46.406 may only be
approved if the following requirements are met:
1. The IRB finds that the research presents a reasonable opportunity to
further the understanding, prevention, or alleviation of a serious problem
affecting the health or welfare of pregnant women, fetuses or neonates, and
2. The Secretary of DHHS, after consultation with a panel of experts in
pertinent disciplines (for example: science, medicine, ethics, law) and
following opportunity for public review and comment, including a public meeting
announced in the FEDERAL REGISTER, has determined either:
a. That the research in fact satisfies the
conditions of 45 CFR 46.204, as applicable, or
b. All of the following:
i. The research presents a reasonable
opportunity to further the understanding, prevention, or alleviation of a
serious problem affecting the health or welfare of pregnant women, fetuses or
neonates.
ii. The research will be conducted in accord
with sound ethical principles.
iii. Informed consent will be obtained in accord
with the informed consent provisions of subpart A and other applicable subparts
of this part. [45 CFR 46.207]
K. UW-Madison IRBs will assure that all research involving, after
delivery, the placenta, the dead fetus, macerated fetal material, or cells,
tissue, or organs excised from a dead fetus is conducted in a manner consistent
with ethical principles and applicable federal regulations, state law and
institutional policies. See, Belmont Report; 45 CFR 46, Subpart B;
Applying State Law in Human Subjects Research Policy; Fetal
Tissue Policy.
L. According to Wisconsin law, children under 18 years of age who are or
have been married, who have given birth or who have been freed from the care,
custody and control of their parents, with little likelihood of returning to
the care, custody and control prior to marriage or prior to reaching the age of
majority are emancipated and, therefore, are consented as adults.
M. The UW-Madison SBS IRB does not allow the inclusion of pregnant women in
research, in which the investigator will have the participants drink alcohol.
N. Before approving drug studies involving pregnant women or women of
child-bearing age, the health sciences IRBs will review the following:
1. Effect of drug on reproductive health, including teratogenic effects
2. Whether protocol includes pregnancy checks in recruitment plan or as
requirement of on-going participation
3. Whether protocol requires participants to notify investigator if
participant becomes pregnant
4. Whether protocol describes procedures if pregnancy occurs:
a. Participant removed from study
b. Counseling provided about possible outcome
due to research participation
IX. Research Involving Other Vulnerable Groups
A. Individuals with Impaired Decision-making Capacity
1. UW-Madison IRBs review protocols involving individuals with impaired
decision-making capacity who are likely to be vulnerable to coercion or undue
influence to assure that additional safeguards are included in research
protocols to protect the rights and welfare of these participants, as required
by federal regulations as well as applicable ethical principles, state law and
institutional policies . Belmont Report; 46 CFR
46.111(b); 21 CFR 56.111(b); WSA 51.61(1)(j), 51.61(4), 54.15,
54.25, 54.46 and 55.07. See, also, UW-Madison Applying State
Law in Human Subjects Research Policy; Research with Adults Lacking Consent
Capacity Policy.
2. To approve research involving individuals with impaired decision-making
capacity, UW-Madison IRBs must find that the criteria set forth in the
UW-Madison’s Research with Adults Lacking Consent Capacity Policy are
satisfied. This policy does not apply if either of the following conditions is
true:
a. The research will occur outside the state of Wisconsin.
If the subjects lacking capacity to consent are at performance sites outside of
Wisconsin, this policy will not apply to that site. Instead, the law of the
state where the subjects are located will prevail.
b. The research involves patients with a
psychiatric diagnosis. Special considerations, and in some cases special
rules, may apply to such research, including additional required protections
for subjects.
If either of the above conditions applies to
the research being reviewed, please consult with an attorney in the UW-Madison
Office of Administrative Legal Services.
3. Definitions. See, Research with Adults Lacking Consent Capacity
Policy.
4. For Veterans Affairs Medical Center (VAMC) research involving adults
unable to consent, see, VA Handbook 1200.5, paragraph 11 and
Appendix D; see, also, Research with Adults Lacking Consent Capacity
Policy.
B. Individuals Receiving Protective Services or Treatment for Mental Illness,
Substance Abuse or Alcohol Dependency in Wisconsin
1. Research involving individuals receiving protective services,
voluntarily or involuntarily, because of aging, chronic mental illness,
developmental disabilities or like incapacities or receiving inpatient or
outpatient treatment for mental illness, development disabilities or substance
and alcohol dependency in Wisconsin must comply with the special conditions
imposed by Wisconsin law. Wisconsin Mental Health Code, WSA 51.61(1)(j),
51.61(4); Wisconsin Protective Services statute, WSA 55.07. For
additional information, consult with an attorney in the UW-Madison Office of
Administrative Legal Services. See, also, Applying State
Law in Human Subjects Research Policy.
2. When UW-Madison IRBs review research that involves such individuals,
the IRBs consider:
a. rationale and justification for involvement in
research of individuals receiving such services, including an explanation as to
why individuals not receiving such services could not be used.
b. the method by which the investigator will
assess whether the individual is capable of consent and, if not, whether an authorized
legal representative is available to consent to participation in research on
behalf of the individual. For additional information, consult with an attorney
in the UW-Madison Office of Administrative Legal Services. See, also, Research
with Adults Lacking Consent Capacity Policy.
c. whether state law requirements have been
satisfied. Wisconsin Mental Health Code, WSA 51.61(1)(j), 51.61(4); Wisconsin
Protective Services statute, WSA 55.07. For additional information,
consult with an attorney in the UW-Madison Office of Administrative Legal
Services. See, also, Applying State Law in Human Subjects Research Policy.
i.
written permission has been obtained from the appropriate officials at
the institution providing the services to the participant for the conduct of
the research at that institution, and
ii.
the research may also need to be approved by the Wisconsin Department of
Health and Family Services (DHFS). (consult with UW-Madison Legal Services
department). Wisconsin Mental Health Code, WSA 51.61(1)(j), 51.61(4); Wisconsin
Protective Services statute, WSA 55.07; Applying State Law in Human
Subjects Research Policy.
C. Institutionalized Individuals
1. Institutionalized individuals are those individuals who are
voluntarily or involuntarily residing in an institution, such as a nursing home
or residential psychiatric institution, because of physical or mental
conditions. Characteristics of the institutional setting create circumstances
that may compromise the voluntary nature of participation in research.
2. UW-Madison IRBs will approve research involving institutionalized
individuals, only if the research includes adequate safeguards to protect the
rights and welfare of these participants, as required by ethical principles and
applicable federal regulations, state law and institutional policies. See, Belmont
Report; 46 CFR 46.111(b); 21 CFR 56.111(b); WSA
51.61(1)(j), 51.61(4) and 55.07; Applying State Law in Human Subjects Research
Policy; Research with Adults Lacking Consent Capacity Policy.
3. Ethical principles suggest that persons who are institutionalized,
particularly if disabled, should not be chosen for studies that bear no
relation to their situation just because it would be convenient for the
researcher. Nevertheless, IRBs should not assume that all institutionalized
individuals are incapable of competent and voluntary consent.
4. When UW-Madison IRBs review research that involves institutionalized
individuals, the IRBs consider:
a. rationale and justification for involvement in
research of institutionalized participants, including an explanation as to why
non-institutionalized individuals could not be used.
b. the method by which the investigator will
assess whether the institutionalized individual is capable of consent and, if
not, whether an appropriate legal representative is available to consent to
participation in research on behalf of the institutionalized individual. For
additional information, consult with the UW-Madison Office of Administrative
Services.
c. if an institutionalized individual is
receiving protective services or treatment for mental illness, substance abuse
or alcohol dependency in Wisconsin, whether state law requirements have been
satisfied. See, Section IV.B, above. Wisconsin Mental Health Code, WSA
51.61(1)(j), 51.61(4); Wisconsin Protective Services statute, WSA
55.07; Applying State Law in Human Subjects
Research Policy.
D. International Research Participants
1. When UW-Madison IRBs review research that involves participants
residing in other countries, the IRBs consider:
a. whether additional safeguards are necessary to
protect the welfare, safety, privacy and confidentiality of these participants
in light of legal, cultural and political considerations [See, International
Research Guidance]
b. whether any additional safeguards are described
in the protocol, and
c. whether the additional safeguards are adequate
to protect participants.
d. the most appropriate method of obtaining
informed consent, taking into account the literacy level of the subjects and
confidentiality concerns.
i. In some cases, oral consent may be more
appropriate than written consent because signing a consent form would put the
participants at greater risk.
ii. Consent should always be obtained in the
native language of the participants. The consent form or oral consent script
must be provided to the IRB in the participant’s native language and an English
translation must be provided.
E. Non-English Speaking Participants
1. Consent should always be obtained in the native language of the
participants. A consent form or oral consent script in the participant’s native
language and an English translation must be provided to the IRB.
2. When UW-Madison IRBs review research that involves non-English speaking
participants, the IRBs consider:
a. Whether the enrollment of non-English
speaking participants is justified by the research questions
b. Whether recruitment and consent documents are
translated into the native language of participants.
c. Whether the individuals communicating
information to the participant or the representative during the consent process
will provide that information in language understandable to the participant or
the representative.
F. Illiterate Participants
1. If participants are illiterate, the IRB may require an oral consent
process or the use of a subject advocate.
G. Participants with Status Relationships
2. In most cases, UW-Madison IRBs do not allow
direct recruitment of participants by someone in a status relationship with
those individuals (e.g., supervisor/employee, faculty member/student). See,
Recruitment of Subjects with Status Relationships (Relatives of Research Staff,
Employees, and Students) Guidance.